Category Archives: Eczema

Take a look at some of the biggest movers in the premarket:

General Motors (GM) The automaker reported quarterly earnings of $2.83 per share, beating the consensus estimate of $1.38 a share, helped by strong demand for trucks and SUVs. Revenue was essentially in line with Street forecasts. The shares rose 6.7% in premarket trading as of 7:44 a.m. ET.

Cigna (CI) The insurance company came in 17 cents a share above estimates, with quarterly earnings of $4.41 per share. Revenue also came in above Wall Street forecasts, helped by higher sales in Cigna's health services unit.

Merck (MRK) Merck is buying privately held drugmaker VelosBio for $2.75 billion in cash, in a move designed to boost its oncology treatment pipeline.

Regeneron (REGN) Regeneron earned $8.36 per share for its latest quarter, beating the $7.14 a share consensus estimate. The drugmaker's revenue also came in above forecasts, boosted by improved sales of drugs like eye treatment Eylea and eczema drug Dupixent.

Capri Holdings (CPRI) The company behind luxury brands like Michael Kors reported quarterly earnings of 90 cents per share, well above the 4 cents a share consensus estimate. Revenue beat forecasts as well. Strong demand in China and a surge in online sales helped drive Capri's better-than-expected quarter. The shares jumped 12% in premarket trading as of 7:44 a.m. ET.

Canada Goose (GOOS) The outerwear maker earned 10 cents per share (Canadian) for its second quarter, compared to the consensus estimate of a 3 cents per share loss. Revenue was also above forecasts as online sales jumped and as the company saw strong demand in China for its parkas.

New York Times (NYT) The newspaper publisher doubled estimates with quarterly earnings of 22 cents per share. Revenue was also above estimates, driven by an increase in digital subscriptions.

Hanesbrands (HBI) The apparel maker beat estimates by 3 cents a share, with quarterly earnings of 42 cents per share. Revenue also exceeded forecasts. Hanesbrands saw better sales for its Champion brand, and also reported an overall boost in digital sales. The shares jumped 14% in premarket trading as of 7:44 a.m. ET.

Barrick Gold (GOLD) The mining company increased its dividend by 12.5% after reporting quarterly profit that nearly tripled from a year earlier. Barrick benefited from a surge in gold prices during the quarter. The shares added 2% in premarket trading as of 7:44 a.m. ET.

Becton Dickinson (BDX) The medical products maker beat estimates by 27 cents a share, with quarterly profit of $2.79 per share. Revenue topped estimates as well. Results were boosted by a jump in sales of Covid-19 -related products like testing kits.

Qualcomm (QCOM) Qualcomm reported quarterly earnings of $1.45 per share, beating the consensus estimate of $1.17 a share. Revenue also came in above forecasts and the chipmaker gave an upbeat current-quarter forecast as Apple (AAPL) and other handset makers ramp up production of 5G phones that utilize Qualcomm chips. The shares surged 14% in premarket trading as of 7:44 a.m. ET.

Apple (AAPL) Apple is facing a shortage of power consumption chips for its new iPhone 12 line, according to people with knowledge of the matter who spoke to Bloomberg. Apple declined to comment when contacted by CNBC.

Amazon.com (AMZN) Amazon CEO Jeff Bezos sold more than $3 billion in Amazon shares in August, according to a Securities and Exchange Commission filing. Bezos has sold about $10.2 billion in shares this year, but still owns more than 53 million shares worth about $170 billion.

AstraZeneca (AZN) The drugmaker said it expected to see data from its late-stage trial involving its Covid-19 vaccine candidate later this year. AstraZeneca also reported better-than-expected quarterly sales, although profit fell short of analysts' forecasts.

Aphria (APHA) Aphria will buy craft brewer SweetWater Brewing Co. for $300 million, as the Canadian cannabis producer expands in the U.S. and enters the alcoholic beverages market.

Apache (APA) Apache reported a smaller-than-expected loss for its latest quarter, with the oil producer also accelerating cost cuts. Apache also said capital spending this year would come in at the low end of its prior forecast.

Expedia (EXPE) Expedia reported a quarterly loss of 22 cents per share, compared to forecasts of a 79 cents per share loss. The travel services company's revenue came in above estimates, even as travel demand continues to be impacted by the pandemic. The shares rose 4% in premarket trading as of 7:44 a.m. ET.

Zynga (ZNGA) Zynga lost 11 cents per share for its latest quarter, 2 cents a share smaller than analysts had anticipated. The mobile game maker's revenue above forecasts. Active user numbers rose to record levels, with its games like "Words With Friends" gaining popularity amid the pandemic. The shares lost 5% in premarket trading as of 7:44 a.m. ET.

Match Group (MTCH) Match reported better-than-expected earnings and revenue for the third quarter, as the pandemic helped boost the popularity of its dating services. Tinder, which is Match Group's most widely-used app, saw subscriber numbers jump 16% from a year earlier. The shares rose 4% in premarket trading as of 7:44 a.m. ET.

Original post:
Stocks making the biggest moves in the premarket: General Motors, Cigna, Merck, Regeneron & more - CNBC

Sunday, November 01, 2020

'); } else { $(".fotorama-caption").addClass("remove_caption"); } }) .fotorama();

MOTHERS can pass allergies to offspring while they are developing in the womb, researchers from the Agency for Science, Technology and Research (A*STAR), KK Women's and Children's Hospital (KKH) and Duke-NUS Medical School in Singapore reported last week in the journal Science .

The study, which employed an animal model conducted according to the National Advisory Committee for Laboratory Animal Research (NACLAR) guidelines, shows that the key antibody responsible for triggering allergic reactions, immunoglobulin E (IgE), can cross the placenta and enter the foetus. When inside the foetus, the antibody binds to foetal mast cells, a type of immune cell that releases chemicals that trigger allergic reactions, from runny noses to asthma.

After birth, newborn mice develop allergic reactions to the same type of allergen as their mothers at the time of first exposure unlike adult mice, which require two exposures. Studies in the laboratory also showed that maternal IgE can bind to human foetal mast cells, indicating they might cross the placenta in humans in a similar way.

Dr Florent Ginhoux, senior principal investigator at A*STAR's Singapore Immunology Network (SIgN) and a senior co-author of the study, said: There is currently a significant lack of knowledge on mast cells that are present early on in the developing foetus. Here, we discovered that foetal mast cells phenotypically mature through the course of pregnancy, and can be sensitised by IgE of maternal origin that cross the placental barrier. The study suggests that a highly allergic pregnant mother may potentially transfer her IgE to her baby that consequently develop allergic reactions when exposed to the first time to the allergen.

Allergies begin very early in life, said Associate Professor Ashley St John, an immunologist at Duke-NUS' Emerging Infectious Diseases Programme and a senior co-author of the study. Infants experience allergic responses closely linked with the mother's allergic response in ways that cannot only be explained by genetics. This work emphasises one way that allergic responses can pass from the mother to the developing foetus, and shows how allergies can then persist after birth.

As part of the study, following NACLAR guidelines, researchers exposed mice to ragweed pollen, a common allergen, prior to pregnancy. Mice that developed a sensitivity to the pollen had offspring that also showed an allergic reaction to ragweed. The sensitivity is allergen-specific; the offspring did not react to dust mites, another common allergen.

Notably, the transfer of sensitivity appears to fade with time. The newborn mice had allergic reactions when tested at four weeks, but less or none at six weeks.

The experimental studies were backed up with cellular tests and imaging, which showed maternal IgE bound to foetal mast cells, triggering the mast cells to release chemicals in reaction to an allergen, a process called degranulation.

This study further showed that the IgE transfer across the placenta requires the help of another protein, FcRN. Mice with FcRN knocked out lacked maternal IgE attached to their mast cells, and did not develop allergies after birth.

The study findings potentially open new intervention strategies to limit such transfer to minimise the occurrence of neonatal allergies. Currently, between 10 to 30 per cent of the world's population are affected by allergies. This number is set to continue rising and a solution preventing allergies being passed from mother to child could potentially bring those numbers down over time.

Our research has really exciting findings that may explain the high incidence of early onset atopic dermatitis (eczema) in children of mothers with clinically proven eczema, which parallel findings in our local birth cohort findings, said Professor Jerry Chan, senior consultant, Department of Reproductive Medicine at KKH, senior National Medical Research Council clinician scientist, and vice-chair of research with the Obstetrics and Gynaecology Academic Clinical Programme at the SingHealth Duke-NUS Academic Medical Centre. From a clinical point of view, developing a further understanding in placental transfer of IgE, and the mechanism of foetal mast cell activation would be key to developing strategies to reduce the chance of eczema or other allergies from being transferred from mother to baby.

The authors next aim to better understand the mechanism of IgE transfer through the placenta, how IgE binding to mast cells in foetal skin modulate their functions and how it could affect skin physiology after birth.

ScienceDaily

Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at http://bit.ly/epaper-login

See the original post:
Mothers pass on allergies to offspring - Jamaica Observer

Ex-Kiss FM presenter Adelle Onyango. PHOTO | COURTESY

Former Kiss fm radio presenter Adelle Onyango has revealed how she hated her body for years after she was raped.

In an Instagram post, Adelle, who was in a bikini, said she hated her body because it reminded her of her scars and her rape ordeal.

In 2008, Adelle was raped by a stranger while she was leaving a house party to hit a club in Westlands.

I am so proud of the intentional work Ive done to get to a point of loving my body. For many years I hated it. I dont know, I think at the time parts of it reminded me of getting rapedthe scars. Then came eczema with its own scars as if to mock me, she wrote.

Adelle further indicated that since the rape ordeal and the eczema, a swimming suit became a no for her for years.

Getting into a swimsuit was justa no-no! Which sucked because Ive been a swimmer all my life and I loved it! So I hid it tights, long sleeves, double sleeves, dont swim, the works! I hardly looked at it. Didnt give it the healthy things it needed. For years.yikes!

Over the years however, she disclosed, she had learnt to love her body even though it has been a long journey of healing and acceptance.

But right now I respect and honor the divinity in this body. Its carried me through battlefields and continues to do so to date. Heres to intentional healing. Its hard. It takes time. Im not all the way there. But it really is the gateway to freedom! she concluded.

See more here:
Adelle: I hated my body, it reminded me of my rape ordeal - Nairobi News

A cell-penetrating, anti-inflammatory peptide developed byJacek Hawiger, Louise B. McGavock Chair and Distinguished Professor of Medicine, and licensed to biopharmaceutical companyAmytrx, has been approved by the FDA for testing as a potential therapeutic for mild to moderate eczema. The peptide, known as AMTX-100, has been in clinical trials since March.

The licensing agreement, facilitated by theCenter for Technology Transfer and Commercialization and the Office of the Vice Provost for Research, enables translation of the product of the Hawiger teamsdecades-long academic research from the lab to a clinical setting. The result is the near-term opportunity to improve the health and well-being of people with a wide range of inflammatory and metabolic diseases, including psoriasis, rosacea, acne, herpes type 1 and 2, and shingles.

The research led by Dr.Hawigerhas immense opportunity to address a variety of conditions connected to inflammation, said Vice Provost for Research Padma Raghavan.

AMTX-100 is a peptide, or chain of amino acids, designed to swiftly penetrate the membrane of inflamed cells that were injured by microbial, autoimmune, allergic, metabolic or physical insults. Once inside of cells, AMTX-100 prevents the cells nucleusa command center of inflammationfrom triggering an otherwise unfavorable inflammatory response. Without such intervention that targets nuclear transport checkpoint, cells produce a myriad of chemicals that mediate inflammation and keep affected organs on fire. This peptide has been developed by Hawigersteam to naturally alter the route through which our own proinflammatory proteins cause swelling, redness, fever, pain, and impaired function, without sacrificing the cells ability to grow and carry out its functions. Research has shown that this approach has significantly fewer side effects and safety concerns than many anti-inflammatory drugs addressing the same issue, creating a potentially significant market opportunity.

We are working to safely address a key mechanism of so many diseases and health conditions that make life more difficult than it should be, saidHawiger, also professor of molecular physiology and biophysics. I am very pleased to be at this phase of translational research that reaffirms our vision, shared byAmytrxco-founder and Director Thomas Andrews, to develop this groundbreaking therapeutic approach withAmytrx.

As a co-founder ofAmytrx,Hawigerwill be involved in further study and research on this transformative anti-inflammatory therapy by conducting preclinical studies in experimental models of human disease with high unmet need.

The progression of this work toAmytrxis in no small part thanks to the dedicated efforts of the Center for Technology Transfer and Commercialization team, Raghavan said. They have been incredibly engaged inbringing game-changing innovation from Vanderbilt research labs to the real world.

Dr.Hawigersanti-inflammatory peptide platformis exceptionally promising, said Dr. MattGonda,AmytrxsCEO, president and co-founder. Meaningful researchwith human applicationslike this cannot be kept to academia.There is a need for a commercialization partner to bring it to fruitionin order toreach the public.Amytrxisthrilled to be working togetherto bringscience with such broad implications for unmet medical needs to the bedside, and our therapeuticsa step closer to patientuse.

See original here:
Vanderbilt University anti-inflammatory therapy licensed to Amytrx is now in clinical trials for eczema treatment - Vanderbilt University News

BALLERUP, Denmark & MADISON, N.J.--(BUSINESS WIRE)--NOT FOR USE IN THE UK OR IRELAND

EMBARGOED UNTIL OCTOBER 29, 2020 4:00 pm CET

LEO Pharma A/S, a global leader in medical dermatology, today announced positive results of a Phase 2b dose-finding study with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, during the Late Breaking News session of the European Academy of Dermatology and Venereology (EADV) Virtual 2020.1

Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.2,3 The cream formulation of delgocitinib is an investigational therapy under clinical development and has not been approved by any regulatory authority.

The primary endpoint for the randomized, double-blind, vehicle-controlled, multi-center Phase 2b dose-finding trial was the proportion of adult patients with mild-to-severe CHE who achieved an Investigators Global Assessment (IGA)-CHE score of 0 (clear) or 1 (almost clear) with a 2 point improvement from baseline, at week 16.1 A key secondary endpoint was change in Hand Eczema Severity Index (HECSI) from baseline to week 16.1

The results presented today showed that delgocitinib cream demonstrated a statistically significant dose-response relationship for these endpoints compared to vehicle.1 Across all treatment groups, the majority of adverse events were non-serious, mild or moderate in severity and not considered treatment related.1 In addition, none of the three serious adverse events were considered treatment related,1 and the most frequently reported adverse events were nasopharyngitis, eczema and headache.1

"There is a significant unmet need for additional treatments for long-term control of CHE, which can cause considerable social and employment burden for both individuals and society, said Prof. Margitta Worm, Division of Allergy and Immunology, Department of Dermatology and Allergy, Charit-Universittsmedizin Berlin. The results of this trial showed that delgocitinib cream may have the potential to become a new treatment option for adult patients suffering from mild-to-severe CHE.

CHE is defined as hand eczema (HE) that lasts for more than three months or relapses twice or more within a year.4,5 HE is the most common skin disorder of the hands6 that affects an estimated 1 5% of the general population7 with a one-year prevalence rate of approximately 10%.8 It is an inflammatory, non-infectious skin disorder of the hands and wrists4,9 and can cause itching, blisters, swelling and pain so severe that it can impair the ability to work.4,6,10 In a substantial number of patients, HE can develop into a chronic condition.6

#ENDS#

About Delgocitinib

In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights.

Earlier this year, delgocitinib cream received Fast Track designation for the treatment of moderate-to-severe CHE from the U.S. Food and Drug Administration. The Fast Track process facilitates the development and expedites regulatory review of drugs to treat serious conditions and that demonstrate the potential to address an unmet medical need.11

About LEO Pharma

The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. For more information about LEO Pharma, visit http://www.leo-pharma.com.

References

1 Worm M, et al. The topical pan-JAK inhibitor delgocitinib cream demonstrates dose response in a 16-week phase 2b trial in chronic hand eczema. Presented during the Late Breaking News session of the European Academy of Dermatology and Venereology (EADV) Virtual 2020 on 29 October 2020.

2 Damsky W, and King BA. JAAD; 2017;76(4):736-744.

3 Virtanen AT, et al. BioDrugs. 2019;33:1532.

4 Lynde C, et al. J Cutan Med Surg. 2010;14:26784.

5 Diepgen TL, et al. J Dtsch Dermatol Ges. 2015 Jan;13(1):e122. doi: 10.1111/ddg.12510_1.

6 Bissonnette R, et al. JEADV. 2010;24;120.

7 Christoffers WA, et al. Cochrane Database Syst Rev. 2019;4:CD004055.

8 Thyssen et al. Contact Dermatitis. 2010;62:75-87.

9 Menn T, et al. Contact Dermatitis. 2011;65:312.

10 Politiek K, et al. Contact Dermatitis. 2016;75:6776.

11 U.S. Food and Drug Administration. Fast Track: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track (Accessed October 2020).

The rest is here:
LEO Pharma announces positive results of Phase 2b dose-finding study with delgocitinib cream in adult patients with mild-to-severe chronic hand eczema...

The chilly weather brings with it a lot of skin woes. And these are not limited to adults, even children are prone to dry skin during the winter season. While your babys skin may be soft most of the time, but it might get dry at times. Babies are prone to dry skin during winters, which can lead to problems such as itchy eczema and more. We asked Dr Sirisha Singh, Dermatologist, to share with us some tips for mothers so that they can take care of their babys skin. Along with the tips, she also shared some insights on what might be leading to the problem. Also Read - Dull skin: Reasons why your skin is looking lifeless and home remedies to treat it

Dr Singh explained that the atmospheric humidity reduces during the winter season, which affects our skin and makes it dry. In addition, sitting in front of the heater with your baby can dehydrate your childs skin. Dehydrated and dry skin is more prone to rashes, eczema and other skin allergies. Also Read - Skincare tips: 5 best foods to combat dry skin

There is a particular skin problem called atopic eczema. It is a kind of genetic tendency that makes children more prone to allergies. So, their skin is intrinsically dry, and they have a high tendency of getting red patches on the skin, she added. Atopic eczema is a common condition in babies. Itching, dryness and redness are common symptoms of the skin problem. Also Read - A perfect scalp and hair care routine for your little one

The skin of newborns and infants is very delicate and needs very careful nourishment and gentle care. Changing weather can wreak havoc on the skin and increases the likelihood of rashes and allergic skin issues. Here are a few tips recommended by the dermatologist that you can use.

Published : October 29, 2020 6:44 pm

Originally posted here:
Dermatologist recommended tips to take care of your babys skin during the winter season - TheHealthSite

Naturally smooth skin is one of those things we take for granted when we have it: Washing our face at night or slathering on a tonic is just so effortlessperhaps even thoughtless. When your skin is soft, you tend not to think about it as much; there is simply less to preen about. Then, when you feel a bump, fold, or scar, many people's immediate reaction is: OK, how do I smooth this out again?

And listen, consistently having smooth skin takes patience, consistency, andif we're being honesta pinch of luck. Smooth skin may feel effortlessbut it hardly ever actually is. Not to mention, there are a plethora of reasons your skin feels less than taut. Texture issues can arise from acne (in the form of pimples and pustulesor later as scars), rosacea (a common misdiagnosed symptom is small, whitehead like bumps), eczema (those notorious dry, flaky patches), enlarged pores (which can create rougher, orange-peel-like skin), and fine lines (which create etches and folds). And what will work for acne may not work for something like eczema. Oh, we must also mention that many people have a blend of a few skin conditions or concernsso finding the right routine takes some smart cocktailing. All of this is to say: Achieving smooth skin involves, well, a bit of nuance.

But there are ways to keep your face soft, in the short term as well as long. Here are some of the best expert-approved ways out thereall-natural, of course.

Excerpt from:
How To Get Smooth Skin: The 12 Best Dermatologist-Approved Tips - mindbodygreen.com

The globalatopic dermatitis drugs marketis likely to expand substantially in the years to come owing to progress made in various drug classes. The market is estimated to rise at a double-digit growth rate of 27% CAGR, over the timeframe of forecast, 2019 to 2027. The global atopic dermatitis drugs market is anticipated to acquire prominence reaching value of US$ 19.6 Bn through 2027.

Atopic dermatitis (AD) refers to a common type of eczema, which affects a large percentage of the population across the globe. Atopic dermatitis, though, can happen at any point of time in ones life, but it generally affects children and infants. Atopic dermatitis, however, lessen its impact with age. With increased prevalence of atopic dermatitis is likely to back growth of the global atopic dermatitis drugs market over timeframe of assessment.

Bristol-Myers Squibb Company, Anacor Pharmaceutical Inc., Regeneron Pharmaceuticals, Inc., Novartis International AG, Allergan Plc., and Astellas Pharma, Inc. are some of the renowned companies found in the global atopic dermatitis drugs market.

Request Brochure for Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73639

Increased Awareness about Various Treatment Options to Boost North America Market

The global atopic dermatitis drugs market has been segmented into the major geographies of North America, Europe, Asia Pacific, Middle East and Africa, and Latin Africa. Region-based segmentations offer a detailed view of the market in various parts of the world.

In the global atopic dermatitis drugs market, North America is likely to offer high growth opportunity over the assessment tenure. Growth of the North America atopic dermatitis drugs market is ascribed to the awareness about available treatment options amongst the people. Canada and the U.S. is estimated to spearhead the growth of the regional market owing to early adoption of new medications, increased collaboration between pharmaceutical companies, improved healthcare infrastructure, and better reimbursement policies. All such factors combines add to the growth of the global atopic dermatitis drugs market during the forecast timeframe.

Request for Analysis of COVID19 Impact on Atopic Dermatitis Drugs Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73639

Increased Prevalence of Atopic Dermatitis to Spell Growth for the Market

The global atopic dermatitis drugs market is expected to be primarily driven by the rising occurrences of atopic dermatitis drugs all over the globe. Allergy of any kind plays an important role in the life of a person with atopic dermatitis. This condition generally flares up when a person with atopic dermatitis disease is around substances that can cause allergic reactions. Mostly affecting children and infants, atopic dermatitis, is estimated to account for around 10 to 20% of those suffering from eczema, according to the data of American College of Allergy, Asthma & Immunology.

The global atopic dermatitis drugs market is forecasted to ride high with the introduction of new treatment methods and biologics and improvement in the diagnostics technology. In addition, replacement of second-line and primary therapies along with premium-priced drugs is likely to offer ample scope of growth of the global atopic dermatitis drugs market.

The information shared in this review is based on a TMR report, bearing the title, Atopic dermatitis drugs market (Drug Class Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, and Biologics; Distribution Channel Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2019 to 2027

Buy Atopic Dermatitis Drugs Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=73639&ltype=S

The globalAtopic Dermatitis Drugs Marketis segmented based on:

Drug Class

Distribution Channel

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Excerpt from:
Atopic Dermatitis Drugs Market projected to expand at a CAGR of ~27% from 2019 to 2027 - PRnews Leader

With the impact of the coronavirus disease 2019 (COVID-19) lockdown measures continuing to be felt across the US, access to healthcare resources for the management of allergic disease are still limited.And although in-person services may be offered by clinics, concern or fear over exposure to the virus can certainly hinder patient use of such services.

And yet, certain allergic conditions, such as peanut allergies in high-risk infants, require expedited assessments and active management.

A report written by Douglas Mack, MD, Assistant Clinical Professor, Pediatrics, McMaster University, and colleagues detailed the first known use of a virtually supported home peanut introduction in infant patients at risk of developing peanut allergy. The program was conducted earlier this year in April.

Prior to initiation of the virtual program, infants were screened for eligibility in a private-practice allergist setting using the telehealth platform Doxy.me.

Patients were eligible if they had physician-diagnosed severe eczema, physician diagnosed egg allergy, SPT3 mm or 0.35 kU/L without prior ingestion, perceived high-risk by caregiver, or had caregiver anxiety to introduce a particular food.

Excluded from the study were patients with a history of systemic IgE-mediated reaction to the food in questions; had certain underlying conditions, such as uncontrolled asthma, cardiac conditions, respiratory conditions; or used a beta-blocker.

During this first consultation, parents or guardians were informed about the risks and benefits of either prolonging peanut avoidance until the first in-person visit or participating in the virtually-support food introduction process.

If they chose to proceed with the program, then consent was obtained, and they were prescribed an epinephrine autoinjector and rupatadine.

In the next visit with the physicians, caregivers were then informed about the process, possible symptoms, and treatment.

Then they were instructed to prepare peanut putter by dissolving 2 teaspoons of it in 2-3 teaspoons of hot water, then letting it cool.

Caregivers then gradually introduced 2 g of peanut butter every 10-15 minutes over 45 minutes 1 hour.

If any symptoms occurred, the guardian used the telehealth program to contact the physicians for further assessment. If the physicians were unable to be reached, then caregivers were instructed to administer epinephrine and/or antihistamine or contact emergency medical services.

However, if no symptoms occurred, then the physicians would advise ingestion of the food of similar or increased amounts 2-3 per week.

Mack and colleagues referenced recent clinical guidelines that provide a framework for at-home management of anaphylaxis. They suggest that using these guidelines would be necessary in the event of such reactions during the virtually supported food introduction.

Nonetheless, they noted that no reactions were reported during the food introduction process, which they considered to be consistent with the current evidence that anaphylaxis is rare and non-threatening with first ingestion in infancy. Thus, they emphasized that mild reactions can generally be managed with antihistamine and/or observation.

Even before COVID-19, lack of allergist resources presented significant barriers to the introduction of peanut to at-risk patients where there was hesitance, they wrote.

During COVID-19, the need to provide alternative forms of care is heightened. Virtually supported introduction may represent a future option after COVID-19 to improve access for patients who live in remote areas, or otherwise have limited access to allergists, or for clinicians with overburdened clinics.

They acknowledged that the implementation of such a strategy requires formal evaluation of safety, cost-effectiveness, caregiver/physician acceptability, sustainability, and patient satisfaction.

The report, Virtually supported home peanut introduction during COVID-19 for at-risk infants, was published online in The Journal of Allergy and Clinical Immunology: In Practice.

Read more from the original source:
Virtually Supported Home Peanut Introduction is Viable Option - MD Magazine

Pune, Maharashtra, October 14 2020 (Wiredrelease) Market.Biz :Colloidal Oatmeal Skin Care Products Market Overview

This comprehensive market research report offers of an in-depth outlook on the Global Colloidal Oatmeal Skin Care Products Market encompassing crucial factors such as the overall size of the global Colloidal Oatmeal Skin Care Products market, in both regional and country-wise terms, as well as market share values, an analysis of recent developments and potential opportunities, sales and competitive landscape analysis, expected product launches, technological innovations (both developed and those in-progress), revenue and trade regulation analysis, among other significantly detailed aspects of the global Colloidal Oatmeal Skin Care Products market, in 2020 and beyond.

The global Colloidal Oatmeal Skin Care Products market is anticipated to gain exponential industry growth over the given forecast period of 2020-2030, with a higher projected value, from estimated values in 2020, indexing a CAGRrate by the end of the aforementioned timeline.

Click Here To Get Free Sample PDF

Global Colloidal Oatmeal Skin Care Products Market segmentation:

Market segmentation of the Colloidal Oatmeal Skin Care Products industry is carried out on the basis of Type, Applications, as well as regions and countries. With respect to Type, segmentation is carried out under Medicinal Grade, Cosmetics Grade, and Others. And concerning the applications, segmentation Eczema Cream with Colloidal Oatmeal, Moisturizer with Colloidal Oatmeal, Cleanser with Colloidal Oatmeal, Others, In Colloidal Oatmeal Skin Care Products market, the Moisturizer with Colloidal Oatmeal holds an important share up to 33%, and the second large part is Cleanser with Colloidal Oatmeal;

Colloidal Oatmeal Skin Care Products Market Segments

Type

Medicinal Grade, Cosmetics Grade

Application

Eczema Cream with Colloidal Oatmeal, Moisturizer with Colloidal Oatmeal, Cleanser with Colloidal Oatmeal, Others, In Colloidal Oatmeal Skin Care Products market, the Moisturizer with Colloidal Oatmeal holds an important share of up to 33%, and the second large part is Cleanser with Colloidal Oatmeal

Regions and Countries Level Analysis:

An in-depth analysis of specified regions and their respective countries are carried out to ensure that the exact detailing of the Colloidal Oatmeal Skin Care ProductsBusiness footprint and its sales demographics are effectively captured with precision, to allow our users to utilize this data to the fullest of their abilities.

Any Query? Do Enquiry @ https://market.biz/report/global-colloidal-oatmeal-skin-care-products-market-gm/#inquiry

The report offers a brief evaluation of the growth and other detail of the Colloidal Oatmeal Skin Care Products Market in important countries (regions), including:

North America Europe Asia Pacific Latin America The Middle East and Africa

Competitive Landscape of the Colloidal Oatmeal Skin Care Productsindustry Share Analysis:

Our analysis of the Colloidal Oatmeal Skin Care Products markets competitive landscape will include market competition examination, by company, its respective overview, business description, product portfolio, key financials, etc. We also include market probability scenarios, a PEST analysis, Porter Five Forces analysis, supply-chain analysis, as well as market expansion strategies.

The major players covered in Colloidal Oatmeal Skin Care Products Market are:

Johnson & Johnson?AVEENO?, Croda, Lantmnnen?Avenacare?, Swedish Oat Fiber AB?Naturex SA?, Quaker Oats Company, Morning Foods, Grain Millers

BUY Colloidal Oatmeal Skin Care Products Market Research Report Here

Reasons to Get this Report:

In an insight outlook, this research report has dedicated to several quantities of analysis industry research (global industry trends) and global Colloidal Oatmeal Skin Care Products market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of global Colloidal Oatmeal Skin Care Productsmarket; high-growth regions; and market drivers, restraints, and also market chances.

The analysis covers the global Colloidal Oatmeal Skin Care Products Business and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Colloidal Oatmeal Skin Care Products Industry across sections such as also application and representatives. Additionally, the analysis also has a comprehensive review of the crucial players on the global Colloidal Oatmeal Skin Care Products market together side their company profiles, SWOT analysis, latest advancements, and business plans.

Chapter 1:

This section will give you an insight into the global Colloidal Oatmeal Skin Care Products market as a whole, proceeding to lend a descriptive overview of this industry.

Chapter 2:

This section now delves further into the anatomy of the global Colloidal Oatmeal Skin Care Products market, detailing market segmentation with respective growth rates and revenue share comparisons.

Chapter 3-7:

The following chapters will comprise of a comprehensive analysis of the global Colloidal Oatmeal Skin Care Products markets segmentation with respect to the various regions and countries.

Check Out The Complete Toc Here: https://market.biz/report/global-colloidal-oatmeal-skin-care-products-market-gm/#toc

Contact Us:

Office Addresses: 420 Lexington Avenue Suite 300New York City, NY 10170, United StatesUSA/Canada Tel No: +1-857-2390696Email: inquiry@market.biz

This content has been published by Market.Biz company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.

See the original post:
Global Colloidal Oatmeal Skin Care Products Market Forecast Probabilities, Growth Expectations, Reve - PharmiWeb.com